Abbott's Kaletra Needs Stronger Warnings To Discourage Off-Label Use In Neonates, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott's combination protease inhibitor causes serious toxicity in newborns, the agency will tell its Pediatric Advisory Committee.